JP2023099094A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023099094A5 JP2023099094A5 JP2023073187A JP2023073187A JP2023099094A5 JP 2023099094 A5 JP2023099094 A5 JP 2023099094A5 JP 2023073187 A JP2023073187 A JP 2023073187A JP 2023073187 A JP2023073187 A JP 2023073187A JP 2023099094 A5 JP2023099094 A5 JP 2023099094A5
- Authority
- JP
- Japan
- Prior art keywords
- initiation
- treatment
- monthly
- disease
- administrations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 29
- 201000011190 diabetic macular edema Diseases 0.000 claims description 29
- 229940116862 faricimab Drugs 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 claims description 5
- 102000009075 Angiopoietin-2 Human genes 0.000 claims 1
- 108010048036 Angiopoietin-2 Proteins 0.000 claims 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 102000047825 human ANGPT2 Human genes 0.000 claims 1
- 102000058223 human VEGFA Human genes 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 description 66
- 201000010099 disease Diseases 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 230000009266 disease activity Effects 0.000 description 14
- 206010064930 age-related macular degeneration Diseases 0.000 description 13
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 208000014245 Ocular vascular disease Diseases 0.000 description 11
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 230000004304 visual acuity Effects 0.000 description 8
- 229940076783 lucentis Drugs 0.000 description 7
- 208000002780 macular degeneration Diseases 0.000 description 7
- 229960003876 ranibizumab Drugs 0.000 description 7
- 230000002207 retinal effect Effects 0.000 description 7
- 201000006165 Kuhnt-Junius degeneration Diseases 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 102100034608 Angiopoietin-2 Human genes 0.000 description 4
- 101000955962 Homo sapiens Vacuolar protein sorting-associated protein 51 homolog Proteins 0.000 description 4
- 238000012014 optical coherence tomography Methods 0.000 description 3
- 108010081667 aflibercept Proteins 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011268 retreatment Methods 0.000 description 2
- 229960002833 aflibercept Drugs 0.000 description 1
- 229950000025 brolucizumab Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229940051306 eylea Drugs 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025034492A JP2025084976A (ja) | 2018-02-06 | 2025-03-05 | 眼科疾患の処置 |
| JP2025034493A JP2025084977A (ja) | 2018-02-06 | 2025-03-05 | 眼科疾患の処置 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862627103P | 2018-02-06 | 2018-02-06 | |
| US62/627,103 | 2018-02-06 | ||
| US201862729333P | 2018-09-10 | 2018-09-10 | |
| US62/729,333 | 2018-09-10 | ||
| JP2022000341A JP7273204B2 (ja) | 2018-02-06 | 2022-01-05 | 眼科疾患の処置 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022000341A Division JP7273204B2 (ja) | 2018-02-06 | 2022-01-05 | 眼科疾患の処置 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025034493A Division JP2025084977A (ja) | 2018-02-06 | 2025-03-05 | 眼科疾患の処置 |
| JP2025034492A Division JP2025084976A (ja) | 2018-02-06 | 2025-03-05 | 眼科疾患の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023099094A JP2023099094A (ja) | 2023-07-11 |
| JP2023099094A5 true JP2023099094A5 (enExample) | 2024-12-20 |
| JP7646727B2 JP7646727B2 (ja) | 2025-03-17 |
Family
ID=65352014
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020536578A Active JP7005772B2 (ja) | 2018-02-06 | 2019-02-05 | 眼科疾患の処置 |
| JP2022000341A Active JP7273204B2 (ja) | 2018-02-06 | 2022-01-05 | 眼科疾患の処置 |
| JP2023073187A Active JP7646727B2 (ja) | 2018-02-06 | 2023-04-27 | 眼科疾患の処置 |
| JP2025034493A Pending JP2025084977A (ja) | 2018-02-06 | 2025-03-05 | 眼科疾患の処置 |
| JP2025034492A Pending JP2025084976A (ja) | 2018-02-06 | 2025-03-05 | 眼科疾患の処置 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020536578A Active JP7005772B2 (ja) | 2018-02-06 | 2019-02-05 | 眼科疾患の処置 |
| JP2022000341A Active JP7273204B2 (ja) | 2018-02-06 | 2022-01-05 | 眼科疾患の処置 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025034493A Pending JP2025084977A (ja) | 2018-02-06 | 2025-03-05 | 眼科疾患の処置 |
| JP2025034492A Pending JP2025084976A (ja) | 2018-02-06 | 2025-03-05 | 眼科疾患の処置 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210139576A1 (enExample) |
| EP (1) | EP3749359A1 (enExample) |
| JP (5) | JP7005772B2 (enExample) |
| KR (2) | KR20240093772A (enExample) |
| CN (4) | CN119733046A (enExample) |
| AU (3) | AU2019219004B2 (enExample) |
| CA (1) | CA3088355A1 (enExample) |
| IL (1) | IL276383B2 (enExample) |
| MX (1) | MX2020007527A (enExample) |
| SG (1) | SG11202006712XA (enExample) |
| TW (3) | TW202535932A (enExample) |
| WO (1) | WO2019154776A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| IL276158B2 (en) | 2018-01-26 | 2024-07-01 | Univ California | Methods and preparations for the treatment of angiogenic disorders using anti-VEGF factors |
| JP2021514656A (ja) | 2018-03-02 | 2021-06-17 | コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． | Ｉｌ−６抗体ならびにその融合構築物およびコンジュゲート |
| CN119303075A (zh) * | 2019-08-06 | 2025-01-14 | 豪夫迈·罗氏有限公司 | 眼科疾病的个性化治疗 |
| US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| BR112022010113A2 (pt) | 2019-11-25 | 2022-09-06 | Univ California | Inibidores de vegf de longa ação para neovascularização intraocular |
| CN116323663A (zh) * | 2020-09-04 | 2023-06-23 | 豪夫迈·罗氏有限公司 | 与vegf-a和ang2结合的抗体及其使用方法 |
| WO2022057888A1 (zh) * | 2020-09-17 | 2022-03-24 | 江苏恒瑞医药股份有限公司 | 特异性结合vegf和ang-2的双特异性抗原结合分子 |
| EP4313148A4 (en) * | 2021-03-30 | 2025-02-19 | Abpro Corporation | METHODS FOR TREATING CHOROIDAL NEOVASCULARIZATION WITH MULTI-SPECIFIC ANTI-ANG2 X VEGF ANTIBODIES |
| WO2022231930A1 (en) | 2021-04-26 | 2022-11-03 | Celanese Eva Performance Polymers Llc | Implantable device for sustained release of a macromolecular drug compound |
| EP4392038A4 (en) * | 2021-08-23 | 2025-06-11 | Avirmax Biopharma Inc. | COMPOSITIONS AND METHODS FOR TRANSGENE EXPRESSION |
| CN117100845A (zh) * | 2022-10-24 | 2023-11-24 | 景泽生物医药(合肥)股份有限公司 | 重组人奥克纤溶酶在制备治疗脉络膜血管疾病药物中的用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| KR100870353B1 (ko) | 1997-04-07 | 2008-11-25 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체 |
| DE69830901T2 (de) | 1997-05-02 | 2006-05-24 | Genentech Inc., San Francisco | ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| AR060070A1 (es) | 2006-03-24 | 2008-05-21 | Merck Patent Gmbh | Dominios proteicos heterodimericos obtenidos por ingenieria |
| JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| AU2010245011B2 (en) | 2009-04-27 | 2015-09-03 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| WO2011090762A1 (en) | 2009-12-29 | 2011-07-28 | Emergent Product Development Seattle, Llc | Heterodimer binding proteins and uses thereof |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| EP2569337A1 (en) | 2010-05-14 | 2013-03-20 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| JP6167040B2 (ja) | 2010-11-05 | 2017-07-19 | ザイムワークス，インコーポレイテッド | Ｆｃドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計 |
| SG10202111177VA (en) * | 2011-01-13 | 2021-11-29 | Regeneron Pharma | Use of a vegf antagonist to treat angiogenic eye disorders |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| CA2859667C (en) | 2011-12-20 | 2022-05-24 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
| RS59263B1 (sr) | 2012-04-20 | 2019-10-31 | Merus Nv | Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula |
| HRP20181595T1 (hr) * | 2012-07-13 | 2018-12-14 | Roche Glycart Ag | Bispecifična anti-vegf/anti-ang-2 protutijela i njihova upotreba u liječenju očnih krvožilnih bolesti |
| CA3098856C (en) * | 2012-08-21 | 2023-10-17 | Opko Pharmaceuticals, Llc | Ophthalmic liposome formulations for treating posterior segment disease |
| ES2871383T3 (es) * | 2013-04-29 | 2021-10-28 | Hoffmann La Roche | Anticuerpos asimétricos modificados que se unen al receptor de Fc y procedimientos de uso |
| KR20150063728A (ko) | 2013-12-02 | 2015-06-10 | 삼성전자주식회사 | 항 VEGF-C/항 Ang2 이중 특이 항체 |
| TWI761959B (zh) * | 2014-11-07 | 2022-04-21 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
| US20160144025A1 (en) * | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| EP3230316B1 (en) * | 2014-12-11 | 2022-01-05 | Bayer HealthCare LLC | Treatment of age related macular degeneration with a small active choroidal neovascularization lesion |
| AR103477A1 (es) * | 2015-01-28 | 2017-05-10 | Lilly Co Eli | Compuestos de vegfa / ang2 |
| EP3454903A4 (en) | 2016-05-13 | 2020-08-19 | Askgene Pharma, Inc. | NEW DOUBLE ANTAGONISTS OF ANGIOPOIETIN 2, VEGF |
| AU2017286676B2 (en) * | 2016-06-17 | 2024-07-25 | F. Hoffmann La-Roche Ag | Purification of multispecific antibodies |
-
2019
- 2019-02-05 CA CA3088355A patent/CA3088355A1/en active Pending
- 2019-02-05 CN CN202411925146.7A patent/CN119733046A/zh active Pending
- 2019-02-05 EP EP19703978.7A patent/EP3749359A1/en active Pending
- 2019-02-05 CN CN202411926524.3A patent/CN119770646A/zh active Pending
- 2019-02-05 KR KR1020247016479A patent/KR20240093772A/ko active Pending
- 2019-02-05 SG SG11202006712XA patent/SG11202006712XA/en unknown
- 2019-02-05 IL IL276383A patent/IL276383B2/en unknown
- 2019-02-05 CN CN201980011416.4A patent/CN111699004A/zh not_active Withdrawn
- 2019-02-05 CN CN202510108289.7A patent/CN119909169A/zh active Pending
- 2019-02-05 JP JP2020536578A patent/JP7005772B2/ja active Active
- 2019-02-05 WO PCT/EP2019/052704 patent/WO2019154776A1/en not_active Ceased
- 2019-02-05 MX MX2020007527A patent/MX2020007527A/es unknown
- 2019-02-05 KR KR1020207025450A patent/KR20200119274A/ko not_active Ceased
- 2019-02-05 AU AU2019219004A patent/AU2019219004B2/en active Active
- 2019-02-11 TW TW114116623A patent/TW202535932A/zh unknown
- 2019-02-11 TW TW108104518A patent/TWI831764B/zh active
- 2019-02-11 TW TW113103154A patent/TWI885720B/zh active
-
2020
- 2020-08-05 US US16/985,477 patent/US20210139576A1/en not_active Abandoned
-
2022
- 2022-01-05 JP JP2022000341A patent/JP7273204B2/ja active Active
-
2023
- 2023-02-09 US US18/166,996 patent/US20230416353A1/en active Pending
- 2023-04-27 JP JP2023073187A patent/JP7646727B2/ja active Active
-
2025
- 2025-03-05 JP JP2025034493A patent/JP2025084977A/ja active Pending
- 2025-03-05 JP JP2025034492A patent/JP2025084976A/ja active Pending
- 2025-08-22 AU AU2025220842A patent/AU2025220842A1/en active Pending
- 2025-08-22 AU AU2025220841A patent/AU2025220841A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023099094A5 (enExample) | ||
| KR102412023B1 (ko) | 레날리도마이드 또는 포말리도마이드 및 ｃｄ38 항체-감쇠 인터페론-알파 구성체의 조합, 및 이의 용도 | |
| CN109715189B (zh) | 靶向VE-PTP(HPTP-β)的人源化单克隆抗体 | |
| IL276383B2 (en) | Treatment of ophthalmologic diseases | |
| US20100047204A1 (en) | Use of organic compounds | |
| CN109071656A (zh) | 检查点调节物拮抗剂 | |
| CN106029096A (zh) | 用于治疗具有未被中等剂量他汀疗法充分控制的高胆固醇血症的患者的方法 | |
| CN106794244A (zh) | 用于降低心血管风险的方法 | |
| JP2025530139A (ja) | 抗ＦｃＲＮ抗体を用いた慢性炎症性脱髄性多発神経障害の治療方法 | |
| JP7579706B2 (ja) | 体組成を変更するための方法 | |
| JP2017535285A5 (enExample) | ||
| JP2019521156A5 (enExample) | ||
| JP7722991B2 (ja) | 抗ｆｃｒｎ抗体を用いた温熱自己免疫性溶血性貧血の治療方法 | |
| US20130004486A1 (en) | Treatment of vascularized pigment epithelial detachment with anti-vegf therapy | |
| JP2009538916A5 (enExample) | ||
| CN109562166B (zh) | 一种眼用药物组合物及其用途 | |
| CN113195532A (zh) | 使用针对瘦素受体、gdf8和活化素a的拮抗剂增加体重和瘦肌肉质量的组合物和方法 | |
| JP2025528527A (ja) | 抗ＦｃＲＮ抗体を用いたグレーブス病の治療方法 | |
| CN116710137A (zh) | 用于在治疗眼部疾病的方法中使用的vegf拮抗剂 | |
| WO2021018191A1 (zh) | Il-17拮抗剂治疗自身免疫疾病的方法 | |
| JPWO2022245739A5 (enExample) | ||
| WO2018096467A1 (en) | Methods of treating acne using interleukin-17 (il-17) antagonists | |
| CN115812079A (zh) | 使用白细胞介素-17(il-17)拮抗剂治疗甲状腺眼病和格雷夫斯眼眶病的方法 | |
| Manzano et al. | Intravitreal toxicity of bevacizumab | |
| TW202237181A (zh) | 治療眼部疾病之方法 |